Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 260 | 2025 | 21162 | 11.080 |
Why?
|
Neoadjuvant Therapy | 92 | 2024 | 2909 | 6.970 |
Why?
|
Sentinel Lymph Node Biopsy | 60 | 2025 | 740 | 6.850 |
Why?
|
Cancer Vaccines | 43 | 2023 | 1042 | 6.840 |
Why?
|
Receptor, erbB-2 | 80 | 2025 | 2588 | 6.840 |
Why?
|
Mastectomy, Segmental | 26 | 2024 | 961 | 4.190 |
Why?
|
Lymph Node Excision | 49 | 2024 | 1274 | 3.910 |
Why?
|
Axilla | 54 | 2024 | 628 | 3.890 |
Why?
|
Neoplasm Staging | 96 | 2024 | 11254 | 3.670 |
Why?
|
Carcinoma, Ductal, Breast | 32 | 2020 | 1094 | 3.240 |
Why?
|
Neoplasm Recurrence, Local | 62 | 2024 | 9433 | 3.200 |
Why?
|
Lymph Nodes | 39 | 2023 | 3471 | 3.090 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 18 | 2024 | 936 | 2.950 |
Why?
|
Receptors, Estrogen | 40 | 2025 | 2247 | 2.770 |
Why?
|
Mastectomy | 36 | 2024 | 1851 | 2.630 |
Why?
|
Carcinoma, Lobular | 18 | 2020 | 480 | 2.620 |
Why?
|
Vaccines, Subunit | 15 | 2023 | 159 | 2.380 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 57 | 2024 | 11854 | 2.080 |
Why?
|
Immunotherapy | 33 | 2024 | 4738 | 2.080 |
Why?
|
Peptide Fragments | 24 | 2023 | 5151 | 2.020 |
Why?
|
Lymphatic Metastasis | 53 | 2023 | 2925 | 2.020 |
Why?
|
Neoplasm, Residual | 12 | 2024 | 1019 | 1.880 |
Why?
|
Chemotherapy, Adjuvant | 49 | 2024 | 3553 | 1.750 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 13 | 2024 | 1105 | 1.640 |
Why?
|
Receptors, Progesterone | 24 | 2025 | 1145 | 1.530 |
Why?
|
Prognosis | 77 | 2025 | 30022 | 1.480 |
Why?
|
Female | 294 | 2025 | 397089 | 1.380 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 13 | 2023 | 892 | 1.280 |
Why?
|
HLA-A2 Antigen | 10 | 2023 | 208 | 1.250 |
Why?
|
T-Lymphocytes, Cytotoxic | 15 | 2020 | 1795 | 1.210 |
Why?
|
Leukocyte Elastase | 5 | 2017 | 114 | 1.200 |
Why?
|
Paclitaxel | 13 | 2024 | 1736 | 1.190 |
Why?
|
Humans | 346 | 2025 | 768393 | 1.130 |
Why?
|
Disease-Free Survival | 25 | 2024 | 6856 | 0.910 |
Why?
|
Antigens, Neoplasm | 11 | 2023 | 1999 | 0.890 |
Why?
|
SEER Program | 6 | 2024 | 1474 | 0.880 |
Why?
|
Inflammatory Breast Neoplasms | 3 | 2024 | 154 | 0.880 |
Why?
|
Aged | 134 | 2024 | 171562 | 0.860 |
Why?
|
Survival Rate | 36 | 2025 | 12870 | 0.830 |
Why?
|
CD8-Positive T-Lymphocytes | 11 | 2020 | 4646 | 0.810 |
Why?
|
Neoplastic Cells, Circulating | 5 | 2019 | 957 | 0.800 |
Why?
|
Middle Aged | 152 | 2025 | 223491 | 0.780 |
Why?
|
Biological Factors | 2 | 2020 | 158 | 0.720 |
Why?
|
Lymphedema | 6 | 2024 | 527 | 0.710 |
Why?
|
Tumor Microenvironment | 15 | 2024 | 3939 | 0.700 |
Why?
|
Adult | 135 | 2024 | 223640 | 0.690 |
Why?
|
Aged, 80 and over | 66 | 2024 | 59686 | 0.670 |
Why?
|
Cytotoxicity, Immunologic | 5 | 2020 | 1355 | 0.670 |
Why?
|
Follow-Up Studies | 53 | 2024 | 39407 | 0.620 |
Why?
|
Parathyroidectomy | 4 | 2007 | 244 | 0.620 |
Why?
|
Folate Receptors, GPI-Anchored | 1 | 2018 | 23 | 0.610 |
Why?
|
Tamoxifen | 4 | 2024 | 968 | 0.610 |
Why?
|
Neoplasm Invasiveness | 17 | 2020 | 3633 | 0.600 |
Why?
|
Combined Modality Therapy | 22 | 2024 | 8562 | 0.600 |
Why?
|
Antineoplastic Agents | 17 | 2024 | 13697 | 0.600 |
Why?
|
Albumins | 1 | 2020 | 577 | 0.580 |
Why?
|
Thyroidectomy | 6 | 2008 | 914 | 0.580 |
Why?
|
Breast | 12 | 2024 | 1975 | 0.570 |
Why?
|
Nomograms | 4 | 2016 | 236 | 0.570 |
Why?
|
Continuity of Patient Care | 1 | 2024 | 1076 | 0.550 |
Why?
|
Prospective Studies | 50 | 2024 | 54920 | 0.530 |
Why?
|
Estrogen Receptor alpha | 2 | 2019 | 581 | 0.510 |
Why?
|
Antigen Presentation | 6 | 2023 | 1251 | 0.500 |
Why?
|
Hyperparathyroidism | 4 | 2007 | 339 | 0.500 |
Why?
|
Testicular Neoplasms | 1 | 2021 | 805 | 0.500 |
Why?
|
Antineoplastic Agents, Hormonal | 2 | 2020 | 1536 | 0.490 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2019 | 827 | 0.480 |
Why?
|
Dendritic Cells | 7 | 2019 | 2749 | 0.480 |
Why?
|
Ferrosoferric Oxide | 1 | 2016 | 349 | 0.470 |
Why?
|
Vaccination | 9 | 2018 | 3431 | 0.460 |
Why?
|
Radiotherapy | 2 | 2020 | 1509 | 0.450 |
Why?
|
Dextrans | 1 | 2016 | 574 | 0.450 |
Why?
|
Neoplasms | 13 | 2022 | 22385 | 0.450 |
Why?
|
Ovarian Neoplasms | 4 | 2019 | 4907 | 0.430 |
Why?
|
Observer Variation | 3 | 2024 | 2623 | 0.420 |
Why?
|
Treatment Outcome | 49 | 2024 | 65379 | 0.420 |
Why?
|
Antibodies, Monoclonal | 13 | 2024 | 9261 | 0.420 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2022 | 5422 | 0.410 |
Why?
|
Hypocalcemia | 3 | 2004 | 203 | 0.410 |
Why?
|
Patient Preference | 1 | 2020 | 947 | 0.410 |
Why?
|
Pathology, Clinical | 1 | 2016 | 376 | 0.400 |
Why?
|
Gene Expression Profiling | 7 | 2024 | 9510 | 0.400 |
Why?
|
Adrenal Gland Neoplasms | 2 | 2008 | 736 | 0.390 |
Why?
|
Adjuvants, Immunologic | 6 | 2016 | 998 | 0.390 |
Why?
|
Mast Cells | 1 | 2019 | 1407 | 0.380 |
Why?
|
Health Plan Implementation | 1 | 2014 | 338 | 0.370 |
Why?
|
Cell Line, Tumor | 20 | 2023 | 17135 | 0.360 |
Why?
|
Retrospective Studies | 46 | 2024 | 81801 | 0.360 |
Why?
|
Biology | 2 | 2024 | 292 | 0.350 |
Why?
|
Adenocarcinoma | 5 | 2011 | 6406 | 0.350 |
Why?
|
Histocompatibility Antigens Class II | 2 | 2019 | 1438 | 0.350 |
Why?
|
GPI-Linked Proteins | 1 | 2012 | 473 | 0.350 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2016 | 1362 | 0.350 |
Why?
|
Clinical Trials, Phase II as Topic | 3 | 2011 | 640 | 0.340 |
Why?
|
Thyroid Neoplasms | 5 | 2022 | 2360 | 0.340 |
Why?
|
Ketones | 2 | 2021 | 182 | 0.340 |
Why?
|
Peptides | 6 | 2024 | 4353 | 0.340 |
Why?
|
Furans | 2 | 2021 | 201 | 0.340 |
Why?
|
Cyclin E | 1 | 2010 | 156 | 0.340 |
Why?
|
Immunotherapy, Adoptive | 2 | 2020 | 1508 | 0.330 |
Why?
|
Artificial Intelligence | 1 | 2024 | 2661 | 0.330 |
Why?
|
Taxoids | 6 | 2023 | 668 | 0.320 |
Why?
|
Genes, erbB-2 | 2 | 2010 | 162 | 0.320 |
Why?
|
Mastectomy, Simple | 3 | 2017 | 23 | 0.310 |
Why?
|
Young Adult | 37 | 2024 | 60049 | 0.300 |
Why?
|
Antigens, Differentiation, B-Lymphocyte | 1 | 2009 | 317 | 0.300 |
Why?
|
Cross-Priming | 4 | 2018 | 75 | 0.300 |
Why?
|
Decision Making | 7 | 2024 | 3953 | 0.300 |
Why?
|
Gene Expression Regulation, Neoplastic | 8 | 2024 | 8634 | 0.300 |
Why?
|
Biopsy, Needle | 5 | 2018 | 1627 | 0.300 |
Why?
|
Lung Neoplasms | 5 | 2022 | 13576 | 0.300 |
Why?
|
Cathepsin G | 3 | 2022 | 41 | 0.290 |
Why?
|
Rosaniline Dyes | 3 | 2019 | 50 | 0.290 |
Why?
|
False Negative Reactions | 6 | 2017 | 575 | 0.290 |
Why?
|
Carboplatin | 4 | 2024 | 799 | 0.290 |
Why?
|
Drug Discovery | 1 | 2015 | 1067 | 0.290 |
Why?
|
Clinical Trials as Topic | 12 | 2024 | 8051 | 0.290 |
Why?
|
Single-Blind Method | 4 | 2020 | 1585 | 0.290 |
Why?
|
Parathyroid Neoplasms | 2 | 2007 | 244 | 0.280 |
Why?
|
Life Expectancy | 2 | 2024 | 1249 | 0.280 |
Why?
|
Carcinoma, Islet Cell | 1 | 2006 | 21 | 0.280 |
Why?
|
Cyclophosphamide | 5 | 2024 | 2226 | 0.270 |
Why?
|
Neoplasm Metastasis | 10 | 2024 | 4921 | 0.270 |
Why?
|
Radiotherapy, Adjuvant | 8 | 2024 | 1794 | 0.270 |
Why?
|
Survival Analysis | 14 | 2021 | 10117 | 0.260 |
Why?
|
Societies, Medical | 6 | 2021 | 3960 | 0.260 |
Why?
|
Magnetite Nanoparticles | 2 | 2019 | 318 | 0.260 |
Why?
|
HLA-A3 Antigen | 4 | 2014 | 34 | 0.250 |
Why?
|
Tumor Escape | 2 | 2020 | 372 | 0.250 |
Why?
|
Sternum | 2 | 2019 | 177 | 0.250 |
Why?
|
United States | 23 | 2024 | 73150 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 10 | 2024 | 6541 | 0.250 |
Why?
|
Cytotoxicity Tests, Immunologic | 1 | 2005 | 317 | 0.250 |
Why?
|
Lithiasis | 1 | 2005 | 19 | 0.240 |
Why?
|
Cecal Diseases | 1 | 2005 | 49 | 0.240 |
Why?
|
Pheochromocytoma | 1 | 2007 | 328 | 0.240 |
Why?
|
Electronic Health Records | 1 | 2022 | 4875 | 0.240 |
Why?
|
Hyperparathyroidism, Primary | 1 | 2007 | 164 | 0.240 |
Why?
|
Rectus Abdominis | 1 | 2005 | 103 | 0.240 |
Why?
|
Hematologic Neoplasms | 1 | 2016 | 1905 | 0.230 |
Why?
|
Biliary Fistula | 1 | 2004 | 38 | 0.230 |
Why?
|
Pancreatic Neoplasms | 4 | 2020 | 5443 | 0.230 |
Why?
|
Medical Oncology | 4 | 2019 | 2349 | 0.230 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2024 | 102 | 0.230 |
Why?
|
Insulinoma | 1 | 2004 | 122 | 0.230 |
Why?
|
Ultrasonography | 8 | 2022 | 6001 | 0.220 |
Why?
|
Appendix | 1 | 2005 | 109 | 0.220 |
Why?
|
Stomach Ulcer | 1 | 2004 | 120 | 0.220 |
Why?
|
T-Lymphocytes | 5 | 2022 | 10267 | 0.220 |
Why?
|
Carcinoma, Papillary | 2 | 2007 | 793 | 0.220 |
Why?
|
Thyroid Nodule | 2 | 2002 | 767 | 0.220 |
Why?
|
Epitopes | 6 | 2012 | 2525 | 0.220 |
Why?
|
Intestinal Fistula | 1 | 2004 | 144 | 0.220 |
Why?
|
Inflammation Mediators | 1 | 2012 | 1890 | 0.210 |
Why?
|
Gallbladder Diseases | 1 | 2004 | 139 | 0.210 |
Why?
|
Patient Selection | 5 | 2023 | 4266 | 0.210 |
Why?
|
Biopsy, Fine-Needle | 2 | 2018 | 1132 | 0.210 |
Why?
|
Abdominal Pain | 3 | 2005 | 1070 | 0.210 |
Why?
|
Hematoma | 2 | 2005 | 768 | 0.210 |
Why?
|
Lymphatic Vessels | 2 | 2022 | 356 | 0.210 |
Why?
|
Heparin, Low-Molecular-Weight | 1 | 2005 | 344 | 0.210 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2004 | 125 | 0.210 |
Why?
|
Biological Products | 2 | 2022 | 934 | 0.210 |
Why?
|
Doxorubicin | 3 | 2024 | 2229 | 0.210 |
Why?
|
Postmenopause | 5 | 2024 | 2518 | 0.210 |
Why?
|
Adaptive Immunity | 2 | 2019 | 731 | 0.210 |
Why?
|
Colonic Diseases | 1 | 2004 | 203 | 0.210 |
Why?
|
Enoxaparin | 1 | 2005 | 391 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3118 | 0.200 |
Why?
|
Models, Statistical | 1 | 2017 | 5099 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3241 | 0.200 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 10377 | 0.200 |
Why?
|
Myeloblastin | 2 | 2012 | 101 | 0.200 |
Why?
|
Genetic Testing | 3 | 2021 | 3587 | 0.200 |
Why?
|
Tumor Cells, Cultured | 5 | 2017 | 6132 | 0.200 |
Why?
|
Practice Guidelines as Topic | 6 | 2017 | 7453 | 0.200 |
Why?
|
Technetium | 2 | 2019 | 326 | 0.200 |
Why?
|
Melanoma | 4 | 2022 | 5705 | 0.190 |
Why?
|
Predictive Value of Tests | 9 | 2021 | 15455 | 0.190 |
Why?
|
Gene Expression Regulation | 2 | 2019 | 11918 | 0.190 |
Why?
|
Pyrazoles | 2 | 2024 | 2021 | 0.190 |
Why?
|
Quality Control | 1 | 2024 | 833 | 0.190 |
Why?
|
Tumor Burden | 6 | 2019 | 1913 | 0.190 |
Why?
|
PTEN Phosphohydrolase | 2 | 2020 | 1119 | 0.190 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2019 | 4411 | 0.190 |
Why?
|
SOXC Transcription Factors | 1 | 2020 | 41 | 0.180 |
Why?
|
Accreditation | 1 | 2024 | 478 | 0.180 |
Why?
|
Adenoma | 3 | 2007 | 2163 | 0.180 |
Why?
|
Carcinoma in Situ | 2 | 2020 | 789 | 0.180 |
Why?
|
Premenopause | 3 | 2021 | 1039 | 0.180 |
Why?
|
Immune Tolerance | 1 | 2010 | 2324 | 0.180 |
Why?
|
Phthalazines | 2 | 2022 | 397 | 0.180 |
Why?
|
Cohort Studies | 14 | 2024 | 41795 | 0.180 |
Why?
|
Melanoma, Experimental | 2 | 2021 | 559 | 0.180 |
Why?
|
Disease Management | 3 | 2019 | 2537 | 0.170 |
Why?
|
Mammaplasty | 3 | 2016 | 1263 | 0.170 |
Why?
|
Databases, Factual | 5 | 2019 | 8075 | 0.170 |
Why?
|
Thyrotoxicosis | 1 | 2001 | 85 | 0.170 |
Why?
|
Drug Resistance, Neoplasm | 5 | 2024 | 5336 | 0.170 |
Why?
|
Hypersensitivity, Delayed | 3 | 2018 | 491 | 0.170 |
Why?
|
Radiopharmaceuticals | 4 | 2023 | 2734 | 0.170 |
Why?
|
Camptothecin | 1 | 2023 | 593 | 0.170 |
Why?
|
Immunization, Secondary | 2 | 2014 | 372 | 0.170 |
Why?
|
Lidocaine | 1 | 2023 | 545 | 0.170 |
Why?
|
Xanthones | 1 | 2019 | 23 | 0.170 |
Why?
|
Parathyroid Hormone | 2 | 2005 | 1804 | 0.160 |
Why?
|
Immunohistochemistry | 4 | 2024 | 11120 | 0.160 |
Why?
|
Glycosylation | 2 | 2019 | 1100 | 0.160 |
Why?
|
Comprehension | 1 | 2024 | 641 | 0.160 |
Why?
|
Health Literacy | 1 | 2024 | 468 | 0.160 |
Why?
|
Animals | 26 | 2024 | 169337 | 0.160 |
Why?
|
Medicare | 4 | 2024 | 6881 | 0.160 |
Why?
|
Mammary Neoplasms, Experimental | 1 | 2021 | 506 | 0.150 |
Why?
|
Nitriles | 1 | 2024 | 984 | 0.150 |
Why?
|
Proportional Hazards Models | 11 | 2018 | 12558 | 0.150 |
Why?
|
Risk | 6 | 2021 | 9636 | 0.150 |
Why?
|
Hormones | 1 | 2022 | 870 | 0.150 |
Why?
|
Immunophenotyping | 2 | 2024 | 1866 | 0.150 |
Why?
|
Transendothelial and Transepithelial Migration | 1 | 2019 | 100 | 0.150 |
Why?
|
Receptors, Androgen | 1 | 2024 | 1083 | 0.150 |
Why?
|
Megakaryocytes | 1 | 2022 | 571 | 0.150 |
Why?
|
General Surgery | 3 | 2015 | 1713 | 0.150 |
Why?
|
Pyrimidinones | 1 | 2020 | 386 | 0.150 |
Why?
|
Multivariate Analysis | 6 | 2018 | 12092 | 0.150 |
Why?
|
Carcinoma | 2 | 2010 | 2341 | 0.150 |
Why?
|
Tracheostomy | 1 | 2002 | 436 | 0.150 |
Why?
|
Registries | 5 | 2022 | 8379 | 0.150 |
Why?
|
Mutation | 11 | 2024 | 30228 | 0.150 |
Why?
|
Frail Elderly | 1 | 2023 | 775 | 0.150 |
Why?
|
Mucin-1 | 2 | 2012 | 538 | 0.140 |
Why?
|
Ferric Compounds | 1 | 2019 | 379 | 0.140 |
Why?
|
Interferons | 2 | 2019 | 716 | 0.140 |
Why?
|
Vertebral Artery | 1 | 1998 | 185 | 0.140 |
Why?
|
Neuropilin-1 | 1 | 2017 | 90 | 0.140 |
Why?
|
Preoperative Care | 2 | 2024 | 2258 | 0.140 |
Why?
|
Vaccines, Attenuated | 1 | 2018 | 314 | 0.140 |
Why?
|
Mice | 16 | 2022 | 82017 | 0.140 |
Why?
|
Anthracyclines | 3 | 2023 | 286 | 0.140 |
Why?
|
Immune System | 1 | 2022 | 801 | 0.130 |
Why?
|
Skin Neoplasms | 4 | 2012 | 5857 | 0.130 |
Why?
|
Quality of Life | 3 | 2024 | 13503 | 0.130 |
Why?
|
Nanomedicine | 1 | 2019 | 292 | 0.130 |
Why?
|
Aromatase Inhibitors | 1 | 2020 | 519 | 0.130 |
Why?
|
Integrins | 1 | 2020 | 843 | 0.130 |
Why?
|
Mediastinal Neoplasms | 1 | 2019 | 403 | 0.130 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2019 | 660 | 0.130 |
Why?
|
Immunoconjugates | 1 | 2023 | 969 | 0.130 |
Why?
|
ROC Curve | 3 | 2019 | 3623 | 0.130 |
Why?
|
Parathyroid Glands | 2 | 2008 | 522 | 0.130 |
Why?
|
Benchmarking | 1 | 2022 | 1058 | 0.130 |
Why?
|
Artifacts | 1 | 2024 | 1930 | 0.130 |
Why?
|
Chromium | 2 | 2006 | 133 | 0.130 |
Why?
|
Signal Transduction | 9 | 2024 | 23631 | 0.130 |
Why?
|
Tissue Distribution | 2 | 2019 | 2299 | 0.130 |
Why?
|
Double-Blind Method | 2 | 2020 | 12456 | 0.130 |
Why?
|
Incidence | 9 | 2018 | 21544 | 0.120 |
Why?
|
Glypicans | 1 | 2015 | 33 | 0.120 |
Why?
|
International Agencies | 1 | 2016 | 245 | 0.120 |
Why?
|
Feasibility Studies | 6 | 2018 | 5313 | 0.120 |
Why?
|
Hypoparathyroidism | 2 | 2008 | 136 | 0.120 |
Why?
|
NF-kappa B | 1 | 2023 | 2489 | 0.120 |
Why?
|
Multigene Family | 1 | 2018 | 1082 | 0.120 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2024 | 9063 | 0.120 |
Why?
|
Antigens, CD | 1 | 2005 | 4031 | 0.120 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 6234 | 0.120 |
Why?
|
Monocytes | 1 | 2024 | 2595 | 0.120 |
Why?
|
Cisplatin | 1 | 2020 | 1661 | 0.120 |
Why?
|
Bone Neoplasms | 3 | 2019 | 2565 | 0.120 |
Why?
|
Intraoperative Care | 1 | 2018 | 771 | 0.120 |
Why?
|
Education, Medical, Continuing | 2 | 2015 | 829 | 0.120 |
Why?
|
Patient Education as Topic | 1 | 2024 | 2337 | 0.110 |
Why?
|
Clinical Competence | 2 | 2015 | 4848 | 0.110 |
Why?
|
Risk Factors | 14 | 2022 | 74962 | 0.110 |
Why?
|
Radiation Oncology | 1 | 2020 | 573 | 0.110 |
Why?
|
Bone Marrow | 1 | 2024 | 2929 | 0.110 |
Why?
|
Surgical Instruments | 3 | 2022 | 386 | 0.110 |
Why?
|
California | 1 | 2018 | 1443 | 0.110 |
Why?
|
Enteral Nutrition | 1 | 1999 | 804 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2002 | 1241 | 0.110 |
Why?
|
Data Collection | 1 | 2022 | 3324 | 0.110 |
Why?
|
Tomography, X-Ray Computed | 5 | 2017 | 20765 | 0.110 |
Why?
|
Point-of-Care Systems | 1 | 2002 | 1238 | 0.110 |
Why?
|
Cerebral Infarction | 1 | 1998 | 975 | 0.110 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2533 | 0.100 |
Why?
|
Kidney Diseases | 1 | 2004 | 2103 | 0.100 |
Why?
|
Extremities | 1 | 2018 | 870 | 0.100 |
Why?
|
Survival | 1 | 2013 | 160 | 0.100 |
Why?
|
Hepatitis C | 1 | 2023 | 1593 | 0.100 |
Why?
|
Adolescent | 12 | 2024 | 89184 | 0.100 |
Why?
|
Brain Stem | 1 | 1998 | 862 | 0.100 |
Why?
|
Immunoenzyme Techniques | 1 | 2015 | 1705 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2018 | 20224 | 0.100 |
Why?
|
Phosphatidylinositol 3-Kinases | 3 | 2024 | 2884 | 0.100 |
Why?
|
Drug Monitoring | 1 | 2018 | 964 | 0.100 |
Why?
|
Social Class | 1 | 2021 | 2009 | 0.100 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2016 | 594 | 0.100 |
Why?
|
Ki-67 Antigen | 2 | 2023 | 628 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2017 | 10478 | 0.100 |
Why?
|
Wounds, Gunshot | 1 | 1998 | 588 | 0.100 |
Why?
|
Nanotechnology | 1 | 2017 | 714 | 0.100 |
Why?
|
Endoscopy | 1 | 2001 | 1857 | 0.100 |
Why?
|
Laparoscopy | 1 | 2003 | 2056 | 0.100 |
Why?
|
Thoracic Wall | 1 | 2013 | 204 | 0.100 |
Why?
|
Pyrimidines | 1 | 2024 | 3048 | 0.090 |
Why?
|
Glycomics | 1 | 2012 | 118 | 0.090 |
Why?
|
Certification | 1 | 2015 | 420 | 0.090 |
Why?
|
Thoracic Neoplasms | 1 | 2013 | 269 | 0.090 |
Why?
|
Intensive Care Units | 2 | 2002 | 3801 | 0.090 |
Why?
|
Academic Medical Centers | 2 | 2023 | 2783 | 0.090 |
Why?
|
Male | 21 | 2022 | 364902 | 0.090 |
Why?
|
Age Factors | 8 | 2019 | 18471 | 0.090 |
Why?
|
Glycopeptides | 1 | 2012 | 225 | 0.090 |
Why?
|
Folate Receptor 1 | 1 | 2011 | 41 | 0.090 |
Why?
|
Xenograft Model Antitumor Assays | 4 | 2020 | 3617 | 0.090 |
Why?
|
Drug Design | 1 | 2016 | 1046 | 0.090 |
Why?
|
Lymphocyte Activation | 2 | 2019 | 5496 | 0.090 |
Why?
|
Arm | 2 | 2024 | 590 | 0.090 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 259 | 0.090 |
Why?
|
Interferon-gamma | 1 | 2019 | 3164 | 0.090 |
Why?
|
Postoperative Period | 3 | 2016 | 1830 | 0.090 |
Why?
|
Metformin | 1 | 2018 | 911 | 0.090 |
Why?
|
Cerebellum | 1 | 1998 | 1514 | 0.090 |
Why?
|
Appendectomy | 2 | 2005 | 443 | 0.090 |
Why?
|
Exosomes | 1 | 2015 | 430 | 0.090 |
Why?
|
Software | 1 | 2024 | 4453 | 0.090 |
Why?
|
Dimerization | 1 | 2012 | 886 | 0.090 |
Why?
|
Postoperative Complications | 5 | 2016 | 15881 | 0.090 |
Why?
|
DNA Primers | 2 | 2012 | 2825 | 0.090 |
Why?
|
Disease Progression | 6 | 2011 | 13646 | 0.090 |
Why?
|
Patient-Centered Care | 1 | 2020 | 1447 | 0.090 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2011 | 300 | 0.080 |
Why?
|
Germ-Line Mutation | 3 | 2022 | 1885 | 0.080 |
Why?
|
Medical Records | 3 | 2013 | 1412 | 0.080 |
Why?
|
Risk Assessment | 9 | 2023 | 24318 | 0.080 |
Why?
|
Algorithms | 2 | 2007 | 14154 | 0.080 |
Why?
|
Specialties, Surgical | 1 | 2014 | 393 | 0.080 |
Why?
|
Anticoagulants | 1 | 2005 | 4843 | 0.080 |
Why?
|
Poverty | 1 | 2021 | 2721 | 0.080 |
Why?
|
Immunologic Memory | 1 | 2016 | 1374 | 0.080 |
Why?
|
Gene Knockdown Techniques | 1 | 2014 | 1608 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2013 | 622 | 0.080 |
Why?
|
Hyperplasia | 2 | 2005 | 1153 | 0.080 |
Why?
|
Time Factors | 7 | 2024 | 40272 | 0.080 |
Why?
|
Mice, Transgenic | 2 | 2021 | 9562 | 0.080 |
Why?
|
G1 Phase | 1 | 2010 | 403 | 0.080 |
Why?
|
Leukemia, Myeloid, Acute | 2 | 2016 | 3620 | 0.080 |
Why?
|
Genetic Predisposition to Disease | 3 | 2021 | 18048 | 0.080 |
Why?
|
Likelihood Functions | 1 | 2012 | 993 | 0.080 |
Why?
|
Technetium Tc 99m Sestamibi | 1 | 2008 | 184 | 0.080 |
Why?
|
Hepatectomy | 1 | 2012 | 588 | 0.080 |
Why?
|
Mice, Nude | 2 | 2015 | 3632 | 0.070 |
Why?
|
Biomedical Research | 1 | 2023 | 3464 | 0.070 |
Why?
|
Molecular Weight | 1 | 2010 | 2172 | 0.070 |
Why?
|
Myeloid Cells | 2 | 2024 | 832 | 0.070 |
Why?
|
Recurrence | 4 | 2012 | 8506 | 0.070 |
Why?
|
Palliative Care | 2 | 2020 | 3643 | 0.070 |
Why?
|
Macrophages | 2 | 2020 | 5796 | 0.070 |
Why?
|
Statistics, Nonparametric | 3 | 2016 | 2862 | 0.070 |
Why?
|
Sensitivity and Specificity | 4 | 2008 | 14737 | 0.070 |
Why?
|
Lymphatic System | 1 | 2009 | 252 | 0.070 |
Why?
|
Socioeconomic Factors | 1 | 2021 | 7861 | 0.070 |
Why?
|
Neck Dissection | 1 | 2008 | 201 | 0.070 |
Why?
|
Appendicitis | 2 | 2005 | 689 | 0.070 |
Why?
|
Neoplasm Transplantation | 2 | 2021 | 2017 | 0.070 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2009 | 330 | 0.070 |
Why?
|
Calcium | 3 | 2007 | 5794 | 0.070 |
Why?
|
Immunity, Innate | 1 | 2019 | 3078 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 1006 | 0.070 |
Why?
|
Meta-Analysis as Topic | 1 | 2012 | 1364 | 0.070 |
Why?
|
Databases, Genetic | 1 | 2014 | 1748 | 0.070 |
Why?
|
Antigen-Presenting Cells | 3 | 2018 | 962 | 0.070 |
Why?
|
Blood Cells | 1 | 2008 | 308 | 0.070 |
Why?
|
Coloring Agents | 3 | 2015 | 564 | 0.070 |
Why?
|
Drainage | 1 | 2012 | 1184 | 0.070 |
Why?
|
Estrogens | 2 | 2024 | 1534 | 0.070 |
Why?
|
Catecholamines | 1 | 2007 | 390 | 0.070 |
Why?
|
Apoptosis | 2 | 2023 | 9516 | 0.060 |
Why?
|
Adrenalectomy | 1 | 2008 | 348 | 0.060 |
Why?
|
Frozen Sections | 1 | 2006 | 154 | 0.060 |
Why?
|
Lysosomal-Associated Membrane Protein 1 | 1 | 2005 | 25 | 0.060 |
Why?
|
Nanoparticles | 1 | 2017 | 1987 | 0.060 |
Why?
|
Pilot Projects | 4 | 2022 | 8731 | 0.060 |
Why?
|
Hypoglycemic Agents | 1 | 2018 | 3108 | 0.060 |
Why?
|
Comorbidity | 1 | 2020 | 10588 | 0.060 |
Why?
|
Adaptation, Physiological | 1 | 2012 | 1315 | 0.060 |
Why?
|
Parathyroid Hormone-Related Protein | 1 | 2006 | 327 | 0.060 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2460 | 0.060 |
Why?
|
Carcinoid Tumor | 1 | 2006 | 224 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2017 | 3610 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 4588 | 0.060 |
Why?
|
Genes, Retinoblastoma | 1 | 2005 | 125 | 0.060 |
Why?
|
Cushing Syndrome | 1 | 2006 | 241 | 0.060 |
Why?
|
Phenotype | 2 | 2021 | 16721 | 0.060 |
Why?
|
Adrenocorticotropic Hormone | 1 | 2006 | 619 | 0.060 |
Why?
|
Protein Binding | 3 | 2012 | 9343 | 0.060 |
Why?
|
Amino Acid Sequence | 3 | 2012 | 13423 | 0.060 |
Why?
|
Melena | 1 | 2004 | 32 | 0.060 |
Why?
|
Hematemesis | 1 | 2004 | 22 | 0.060 |
Why?
|
Colloids | 2 | 2015 | 127 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5891 | 0.060 |
Why?
|
Biopsy | 3 | 2024 | 6808 | 0.060 |
Why?
|
Proteome | 1 | 2014 | 1881 | 0.060 |
Why?
|
Biological Transport | 2 | 2019 | 2085 | 0.060 |
Why?
|
Leukemia | 1 | 2012 | 1526 | 0.060 |
Why?
|
Fecal Impaction | 1 | 2003 | 32 | 0.060 |
Why?
|
Hematocrit | 1 | 2005 | 625 | 0.050 |
Why?
|
Molecular Sequence Data | 3 | 2012 | 17626 | 0.050 |
Why?
|
BRCA1 Protein | 2 | 2020 | 1155 | 0.050 |
Why?
|
Hernia | 1 | 2003 | 68 | 0.050 |
Why?
|
Hemostasis, Surgical | 1 | 2004 | 127 | 0.050 |
Why?
|
Electric Impedance | 1 | 2008 | 795 | 0.050 |
Why?
|
Anti-Ulcer Agents | 1 | 2004 | 112 | 0.050 |
Why?
|
International Normalized Ratio | 1 | 2005 | 382 | 0.050 |
Why?
|
Cognition Disorders | 2 | 2007 | 3985 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9614 | 0.050 |
Why?
|
Ligands | 2 | 2022 | 3283 | 0.050 |
Why?
|
Cyclin D1 | 1 | 2005 | 453 | 0.050 |
Why?
|
Down-Regulation | 1 | 2010 | 2940 | 0.050 |
Why?
|
Protein Interaction Domains and Motifs | 2 | 2017 | 450 | 0.050 |
Why?
|
C-Peptide | 1 | 2004 | 443 | 0.050 |
Why?
|
Contrast Media | 1 | 2016 | 5336 | 0.050 |
Why?
|
Histamine H2 Antagonists | 1 | 2004 | 169 | 0.050 |
Why?
|
Tissue Adhesions | 1 | 2003 | 223 | 0.050 |
Why?
|
Palpation | 1 | 2002 | 166 | 0.050 |
Why?
|
Goiter | 1 | 2002 | 87 | 0.050 |
Why?
|
Multicenter Studies as Topic | 1 | 2007 | 1727 | 0.050 |
Why?
|
Thyroiditis | 1 | 2002 | 86 | 0.050 |
Why?
|
Organ Size | 1 | 2007 | 2268 | 0.050 |
Why?
|
Hypercalcemia | 1 | 2005 | 423 | 0.050 |
Why?
|
Base Sequence | 2 | 2012 | 12422 | 0.050 |
Why?
|
Preoperative Period | 2 | 2017 | 564 | 0.050 |
Why?
|
Obesity | 2 | 2016 | 13084 | 0.050 |
Why?
|
Cross-Over Studies | 2 | 2020 | 2106 | 0.050 |
Why?
|
Age Distribution | 1 | 2007 | 2877 | 0.050 |
Why?
|
Transplantation, Isogeneic | 1 | 2021 | 249 | 0.050 |
Why?
|
Metaplasia | 1 | 2022 | 326 | 0.050 |
Why?
|
Endoscopy, Digestive System | 1 | 2004 | 357 | 0.050 |
Why?
|
Career Mobility | 1 | 2023 | 262 | 0.050 |
Why?
|
Digestive System Surgical Procedures | 1 | 2006 | 584 | 0.050 |
Why?
|
HLA-A1 Antigen | 1 | 2020 | 9 | 0.050 |
Why?
|
Antigens, Viral | 1 | 2005 | 992 | 0.050 |
Why?
|
Retinoblastoma Protein | 1 | 2024 | 673 | 0.050 |
Why?
|
Texas | 2 | 2012 | 409 | 0.050 |
Why?
|
Transcription Factors | 1 | 2020 | 12166 | 0.050 |
Why?
|
Intraoperative Period | 1 | 2001 | 513 | 0.040 |
Why?
|
Immunologic Factors | 2 | 2021 | 1597 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2005 | 1064 | 0.040 |
Why?
|
Computational Biology | 1 | 2012 | 3543 | 0.040 |
Why?
|
Faculty | 1 | 2023 | 384 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8753 | 0.040 |
Why?
|
Multiple Myeloma | 1 | 2018 | 5192 | 0.040 |
Why?
|
Immunoglobulin G | 1 | 2012 | 4570 | 0.040 |
Why?
|
Postoperative Care | 1 | 2006 | 1480 | 0.040 |
Why?
|
Area Under Curve | 2 | 2016 | 1642 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2023 | 794 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2021 | 417 | 0.040 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2024 | 906 | 0.040 |
Why?
|
Workflow | 1 | 2024 | 859 | 0.040 |
Why?
|
Amiodarone | 1 | 2001 | 217 | 0.040 |
Why?
|
Graves Disease | 1 | 2001 | 239 | 0.040 |
Why?
|
Liver Neoplasms | 2 | 2012 | 4365 | 0.040 |
Why?
|
Technology | 1 | 2021 | 296 | 0.040 |
Why?
|
Proteasome Endopeptidase Complex | 2 | 2018 | 1319 | 0.040 |
Why?
|
Intestinal Diseases | 1 | 2003 | 505 | 0.040 |
Why?
|
Gastrectomy | 1 | 2004 | 696 | 0.040 |
Why?
|
Nucleotides, Cyclic | 1 | 2019 | 83 | 0.040 |
Why?
|
Cross-Sectional Studies | 3 | 2024 | 26375 | 0.040 |
Why?
|
Silicon | 1 | 2019 | 143 | 0.040 |
Why?
|
Proto-Oncogene Proteins | 2 | 2015 | 4526 | 0.040 |
Why?
|
Prevalence | 2 | 2024 | 15872 | 0.040 |
Why?
|
Protein Kinase Inhibitors | 1 | 2015 | 5708 | 0.040 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2022 | 566 | 0.040 |
Why?
|
Body Mass Index | 2 | 2016 | 13052 | 0.040 |
Why?
|
Aminopyridines | 1 | 2022 | 580 | 0.040 |
Why?
|
Patient Advocacy | 1 | 2020 | 362 | 0.040 |
Why?
|
Staining and Labeling | 1 | 2022 | 1081 | 0.040 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2023 | 1151 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2004 | 13020 | 0.040 |
Why?
|
Iodine Radioisotopes | 1 | 2022 | 1035 | 0.040 |
Why?
|
Mentors | 1 | 2023 | 672 | 0.040 |
Why?
|
Fluorescent Antibody Technique | 1 | 2022 | 2475 | 0.040 |
Why?
|
Genetic Heterogeneity | 1 | 2021 | 737 | 0.040 |
Why?
|
Mitochondrial Proteins | 1 | 2023 | 977 | 0.040 |
Why?
|
Phagocytes | 1 | 2019 | 294 | 0.040 |
Why?
|
Drug Administration Schedule | 2 | 2020 | 4859 | 0.030 |
Why?
|
Blood Transfusion | 1 | 2004 | 1309 | 0.030 |
Why?
|
Mammary Glands, Human | 1 | 2018 | 202 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2022 | 18362 | 0.030 |
Why?
|
Gene Expression | 2 | 2022 | 7598 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2022 | 864 | 0.030 |
Why?
|
Breast Neoplasms, Male | 1 | 2018 | 212 | 0.030 |
Why?
|
Placebo Effect | 1 | 2021 | 518 | 0.030 |
Why?
|
Antibodies, Blocking | 1 | 2017 | 250 | 0.030 |
Why?
|
Protein Transport | 2 | 2012 | 1958 | 0.030 |
Why?
|
Tissue Donors | 1 | 2006 | 2389 | 0.030 |
Why?
|
Genomics | 2 | 2023 | 5916 | 0.030 |
Why?
|
Glomerular Filtration Rate | 1 | 2005 | 2226 | 0.030 |
Why?
|
Seroma | 1 | 2016 | 74 | 0.030 |
Why?
|
Transcription, Genetic | 1 | 2010 | 7599 | 0.030 |
Why?
|
Cholesterol, HDL | 1 | 2022 | 1820 | 0.030 |
Why?
|
Complement Activation | 1 | 2018 | 447 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2024 | 930 | 0.030 |
Why?
|
Adjuvants, Pharmaceutic | 1 | 2015 | 48 | 0.030 |
Why?
|
Microspheres | 1 | 2019 | 789 | 0.030 |
Why?
|
Radiotherapy, Conformal | 1 | 2019 | 549 | 0.030 |
Why?
|
Military Personnel | 1 | 2005 | 1266 | 0.030 |
Why?
|
Solubility | 1 | 2017 | 1085 | 0.030 |
Why?
|
Endometriosis | 1 | 2003 | 875 | 0.030 |
Why?
|
Epirubicin | 1 | 2015 | 81 | 0.030 |
Why?
|
Infusions, Intravenous | 1 | 2020 | 2226 | 0.030 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2024 | 1901 | 0.030 |
Why?
|
Triglycerides | 1 | 2022 | 2465 | 0.030 |
Why?
|
Patient Satisfaction | 1 | 2007 | 3486 | 0.030 |
Why?
|
AMP-Activated Protein Kinases | 1 | 2018 | 598 | 0.030 |
Why?
|
Fiducial Markers | 1 | 2016 | 134 | 0.030 |
Why?
|
Molecular Targeted Therapy | 2 | 2019 | 2830 | 0.030 |
Why?
|
Magnetic Resonance Imaging | 3 | 2022 | 36849 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2021 | 1397 | 0.030 |
Why?
|
Tumor Suppressor Proteins | 1 | 2005 | 2812 | 0.030 |
Why?
|
Cost of Illness | 1 | 2024 | 1959 | 0.030 |
Why?
|
Vinblastine | 1 | 2016 | 488 | 0.030 |
Why?
|
Amino Acid Motifs | 1 | 2017 | 929 | 0.030 |
Why?
|
Serine | 1 | 2018 | 831 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2019 | 802 | 0.030 |
Why?
|
RNA | 2 | 2022 | 2726 | 0.030 |
Why?
|
Surgical Wound Infection | 1 | 2004 | 1545 | 0.030 |
Why?
|
HCT116 Cells | 1 | 2015 | 405 | 0.030 |
Why?
|
Immunomodulation | 1 | 2018 | 549 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2018 | 1839 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2058 | 0.030 |
Why?
|
Diffusion of Innovation | 1 | 2019 | 732 | 0.030 |
Why?
|
Intubation, Intratracheal | 1 | 2002 | 1359 | 0.030 |
Why?
|
Interleukin-10 | 1 | 2019 | 1184 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2024 | 3230 | 0.030 |
Why?
|
NIH 3T3 Cells | 1 | 2015 | 669 | 0.030 |
Why?
|
Stomach Neoplasms | 1 | 2004 | 1484 | 0.030 |
Why?
|
Case-Control Studies | 3 | 2017 | 22296 | 0.030 |
Why?
|
Flow Cytometry | 1 | 2024 | 5900 | 0.030 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2023 | 2890 | 0.030 |
Why?
|
Cholesterol, LDL | 1 | 2022 | 2398 | 0.030 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 1999 | 887 | 0.030 |
Why?
|
Fatal Outcome | 1 | 1998 | 1837 | 0.030 |
Why?
|
Genes, Insect | 1 | 1994 | 265 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2020 | 2003 | 0.030 |
Why?
|
United States Food and Drug Administration | 1 | 2021 | 1672 | 0.030 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2038 | 0.030 |
Why?
|
Technetium Tc 99m Sulfur Colloid | 1 | 2012 | 63 | 0.030 |
Why?
|
Probability | 2 | 2008 | 2482 | 0.030 |
Why?
|
Thioredoxins | 1 | 1994 | 202 | 0.030 |
Why?
|
Self-Assessment | 1 | 2015 | 401 | 0.030 |
Why?
|
Endoplasmic Reticulum | 1 | 2018 | 1131 | 0.030 |
Why?
|
Diagnostic Imaging | 1 | 2006 | 3541 | 0.030 |
Why?
|
Meiosis | 1 | 1994 | 327 | 0.020 |
Why?
|
Blood Platelets | 1 | 2022 | 2476 | 0.020 |
Why?
|
Immunization | 1 | 2016 | 1219 | 0.020 |
Why?
|
Epitope Mapping | 1 | 2012 | 300 | 0.020 |
Why?
|
Mass Screening | 1 | 2007 | 5451 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2020 | 2433 | 0.020 |
Why?
|
Administration, Oral | 1 | 2019 | 4039 | 0.020 |
Why?
|
Placenta | 1 | 2020 | 1723 | 0.020 |
Why?
|
Cell Line | 1 | 2005 | 15597 | 0.020 |
Why?
|
Immunotherapy, Active | 1 | 2011 | 58 | 0.020 |
Why?
|
Glucose | 1 | 2022 | 4352 | 0.020 |
Why?
|
Antigens, CD34 | 1 | 2012 | 656 | 0.020 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2012 | 881 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2023 | 3627 | 0.020 |
Why?
|
Proteins | 1 | 2005 | 6006 | 0.020 |
Why?
|
ras Proteins | 1 | 2015 | 1058 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2948 | 0.020 |
Why?
|
Fluorouracil | 1 | 2015 | 1655 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2021 | 3579 | 0.020 |
Why?
|
Remission Induction | 1 | 2015 | 2407 | 0.020 |
Why?
|
Kinetics | 1 | 2017 | 6333 | 0.020 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2020 | 1755 | 0.020 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 1 | 2010 | 306 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2020 | 3458 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2022 | 4209 | 0.020 |
Why?
|
Gamma Cameras | 1 | 2008 | 35 | 0.020 |
Why?
|
Congresses as Topic | 1 | 2013 | 810 | 0.020 |
Why?
|
Immunization, Passive | 1 | 2011 | 619 | 0.020 |
Why?
|
RNA Interference | 1 | 2017 | 2836 | 0.020 |
Why?
|
Chronic Disease | 1 | 2003 | 9379 | 0.020 |
Why?
|
Genome, Human | 1 | 2021 | 4450 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2024 | 3413 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13323 | 0.020 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2008 | 359 | 0.020 |
Why?
|
Propensity Score | 1 | 2016 | 1962 | 0.020 |
Why?
|
Brain Neoplasms | 2 | 2024 | 9198 | 0.020 |
Why?
|
Annexin A5 | 1 | 2008 | 104 | 0.020 |
Why?
|
Medication Adherence | 1 | 2019 | 2189 | 0.020 |
Why?
|
Necrosis | 1 | 2012 | 1621 | 0.020 |
Why?
|
Ubiquitination | 1 | 2012 | 1009 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2017 | 6510 | 0.020 |
Why?
|
Phosphorylation | 1 | 2018 | 8326 | 0.020 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1766 | 0.020 |
Why?
|
Cause of Death | 1 | 1998 | 3728 | 0.020 |
Why?
|
Electrodiagnosis | 1 | 2008 | 149 | 0.020 |
Why?
|
Health Services Needs and Demand | 1 | 2015 | 1407 | 0.020 |
Why?
|
Radiography | 1 | 1998 | 6993 | 0.020 |
Why?
|
Consensus | 1 | 2016 | 3212 | 0.020 |
Why?
|
Kidney | 1 | 2002 | 7064 | 0.020 |
Why?
|
Lysosomes | 1 | 2012 | 939 | 0.020 |
Why?
|
Cytokines | 1 | 2021 | 7445 | 0.020 |
Why?
|
Drosophila | 1 | 1994 | 1514 | 0.020 |
Why?
|
Epithelial Cells | 1 | 2018 | 3695 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2008 | 10776 | 0.020 |
Why?
|
Military Medicine | 1 | 2008 | 185 | 0.020 |
Why?
|
Maximum Tolerated Dose | 1 | 2008 | 890 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2012 | 2728 | 0.020 |
Why?
|
Cell Movement | 1 | 2017 | 5215 | 0.020 |
Why?
|
Pregnancy | 2 | 2020 | 30200 | 0.020 |
Why?
|
Graft Survival | 1 | 2016 | 3900 | 0.020 |
Why?
|
Radionuclide Imaging | 1 | 2008 | 1998 | 0.010 |
Why?
|
Antibodies | 1 | 2012 | 2425 | 0.010 |
Why?
|
Cell Count | 1 | 2008 | 1833 | 0.010 |
Why?
|
Choice Behavior | 1 | 2010 | 848 | 0.010 |
Why?
|
Diagnostic Errors | 1 | 2011 | 1280 | 0.010 |
Why?
|
Causality | 1 | 2010 | 1255 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2012 | 4834 | 0.010 |
Why?
|
Safety | 1 | 2008 | 1159 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6350 | 0.010 |
Why?
|
Graft Rejection | 1 | 2016 | 4505 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2021 | 22355 | 0.010 |
Why?
|
Research Design | 1 | 2018 | 6210 | 0.010 |
Why?
|
Immunity, Cellular | 1 | 2008 | 1561 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2007 | 3438 | 0.010 |
Why?
|
Cell Division | 1 | 2008 | 4479 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2012 | 3407 | 0.010 |
Why?
|
Health Status Disparities | 1 | 2012 | 1882 | 0.010 |
Why?
|
B-Lymphocytes | 1 | 2012 | 4785 | 0.010 |
Why?
|
Child | 2 | 2012 | 80891 | 0.010 |
Why?
|
Health Surveys | 1 | 2007 | 4056 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2012 | 5713 | 0.010 |
Why?
|
Transformation, Genetic | 1 | 1994 | 194 | 0.010 |
Why?
|
Oogenesis | 1 | 1994 | 125 | 0.010 |
Why?
|
Embryonic and Fetal Development | 1 | 1994 | 420 | 0.010 |
Why?
|
DNA, Complementary | 1 | 1994 | 1992 | 0.010 |
Why?
|
DNA Transposable Elements | 1 | 1994 | 762 | 0.010 |
Why?
|
Sequence Homology, Amino Acid | 1 | 1994 | 2750 | 0.010 |
Why?
|
Homozygote | 1 | 1994 | 1779 | 0.000 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2012 | 12241 | 0.000 |
Why?
|